MAX-40279 hemifumarate

Overview

MAX-40279 hemifumarate is a dual and orally active inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hemifumarate is also effective against the FLT3 mutants such as FLT3 D835Y , suggesting that it can overcome resistance to Quizartinib ( HY-13001 ) and Sorafenib ( HY-10201 ). MAX-40279 hemifumarate inhibits NDRG1 phosphorylation at Ser330 and suppresses endothelial-to-mesenchymal transition (EndMT). MAX-40279 hemifumarate can be used for the research of acute myelogenous leukemia (AML).

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Breast Cancer | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Signaling Pathways > FLT3 | Products > Signaling Pathways > FGFR

Product Information

• Catalog No.: HY-145723B
• CAS No.: 2388506-43-0
• Molecular Formula: C22H23FN6OS·1/2C4H4O4
• Molecular Weight: 496.57
• Purity: 99.52%
• Storage: -20°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
• Availability: In-stock

Source

Original product source